Moderate Immunodeficiency Does Not Increase Susceptibility to *Salmonella typhimurium aroA* Live Vaccines in Mice

MATEEN IZHAR, LEEL DeSILVA, HEATHER S. JOYSEY, AND CARLOS E. HORMAECHE*

*Microbiology and Parasitology Division, Cambridge University Department of Pathology,
Tennis Court Road, Cambridge CB2 1QP, United Kingdom*

Salmonellae carrying appropriate mutations in genes of the aromatic biosynthesis pathway are effective as live vaccines in animals, and they are candidate typhoid vaccines for human use. They are also very effective as carriers of recombinant antigens from other pathogens to the immune system, eliciting circulatory, secretory, and cell-mediated immunity to foreign antigens. Their attenuation is believed to be due to their requirement for the metabolites *p*-aminobenzoic acid and 2,3-dihydroxybenzoate, which are not available in mammalian tissues. Immunosuppression (e.g., acquired immunodeficiency syndrome) is a major contraindication to the use of live vaccines. If the avirulence of Aro mutants is largely due to their auxotrophy, they should not be markedly more invasive in immunosuppressed animals. We report that wild-type *Salmonella typhimurium* M525 of intermediate virulence was much more invasive in sublethally irradiated BALB/c mice than in normal BALB/c mice, whereas sublethal irradiation had little if any effect on the invasiveness of an *S. typhimurium aroA* vaccine strain apart from a delay in its clearance from the reticuloendothelial system. *xid* mutant CBA/N mice carry an X-linked B-cell functional defect which results in immunoglobulin G3 agammaglobulinemia, and they are known to be more susceptible to salmonellae in late stages of the infection. We found that whereas male (CBA/N × BALB/c)F$_1$ mice (immunodefective) were more susceptible to wild-type *S. typhimurium* C5 than female littermates (immunocompetent), there was no difference in the response to the *S. typhimurium aroA* vaccine strain. The results indicate that moderate immunosuppression does not markedly enhance susceptibility to *S. typhimurium aroA* live vaccines.

Salmonellosis is a major worldwide health problem. There is an increasing interest in the development of live attenuated salmonella vaccines since they provide better protection than the whole-cell killed vaccines, probably because of their ability to induce cellular immunity in addition to humoral immunity (6, 13).

Hoiseth and Stocker (7) constructed *Salmonella typhimurium* strains carrying defined, nonreverting deletions in the *aroA* gene, rendering them avirulent by making them dependent for growth on the aromatic compounds *p*-aminobenzoic acid and 2,3-dihydroxybenzoate, which are not found in mammalian tissues. They were found to be safe and effective live vaccines for mice and, together with Aro mutants of *Salmonella typhi*, are currently being considered for use as live vaccines in domestic animals and humans. They have also been found to be very effective as recombinant vaccines carrying heterologous antigens derived from bacteria, viruses, and parasites (4, 5).

These vaccines could be used in human populations, some members of which may be immunocompromised as a result of being at extremes of age, malnourished, or suffering from concurrent disease or from an immunosuppressive disorder, e.g., acquired immunodeficiency syndrome. Immunosuppression is a major contraindication to the use of live vaccines. However, Aro mutants should not be markedly more invasive in moderately immunosuppressed hosts if their attenuation is due to their auxotrophy.

Immunosuppression is known to increase the susceptibility of mice to wild-type salmonellae. Sublethal irradiation reduces the 50% lethal dose (LD$_{50}$) in oral and intravenous (i.v.) challenge; irradiated mice cannot suppress bacterial growth in the reticuloendothelial system at the end of week

1 of the infection (3). The X-linked *xid* defect also makes mice more susceptible to salmonellae but in the later stages of the infection (16, 17). *xid* causes a B-lymphocyte functional defect with low serum immunoglobulin M and immunoglobulin G3 and is expressed in F$_1$ male mice from crosses of homozygous CBA/N females with male mice from other inbred strains (20–22). The virulence of Aro⁻ salmonellae was explored in these two models.

MATERIALS AND METHODS

Mice. BALB/c mice were bred in this department or in the Wellcome Research Laboratories (Beckenham, Kent, United Kingdom) from breeders originally purchased from Harlan Olac Ltd. (Blackthorn, Bicester, United Kingdom). Male mice 3 to 6 months of age were used. (CBA/N × BALB/c)F$_1$ male and female mice were bred in this department from breeders purchased from Harlan Olac Ltd. Mice used were 3 to 6 months of age.

Irradiation. Mice were whole-body X-irradiated with 350 rads at 48 rads/min from a 240-keV source 24 h before infection (9).

Bacteria. *S. typhimurium* SL3261 (7), M525 (10), and C5 (10) (i.v. LD$_{50}$ for BALB/c mice, ~10^7, ~10^5, and <10^2, respectively) were grown in stationary tryptic soy broth (Oxoid Ltd., London, England) cultures overnight at 37°C, and aliquots were snap frozen and stored in liquid nitrogen. For use, vials were rapidly thawed and diluted in phosphate-buffered saline (pH 7.2) to the desired inoculum strength, which was checked by pour plates.

LD$_{50}$ determinations. Groups of three to six mice were infected i.v. in a tail vein with 0.2 ml of serial 10-fold dilutions of the culture in phosphate-buffered saline. Mortality was recorded over 4 weeks, and the LD$_{50}$ was determined

---

* Corresponding author.

TABLE 1. LD$_{50}$ values (log$_{10}$ CFU) of S. typhimurium aroA
SL3261 and S. typhimurium M525 injected i.v. in irradiated and
control BALB/c mice and S. typhimurium aroA SL3261 and
S. typhimurium C5 in male (immunodefective) and female
(immunocompetent) (CBA/N × BALB/c)F$_1$ mice

Mouse strain	Log$_{10}$ LD$_{50}$ of salmonella strain:		
	SL3261	M525	C5
BALB/c			
Control	7.6	5.3	
Irradiated	7.2	≤1.8	
(CBA/N × BALB/c)F$_1$			
Female	6.5		3.3
Male	6.5		1.4

by the method of Reed and Muench (18). Results are
expressed as log$_{10}$ CFU.

**Enumeration of viable organisms in liver and spleen ho-
mogenates.** Mice were infected i.v. with a sublethal dose of
the desired strain. At intervals, groups of three to four mice
were sacrificed and livers and spleens were homogenized
separately in 10 ml of distilled water with a Colworth
stomacher (A. J. Seward, London, England) as previously

described (8). Viable counts were determined with a Col-
worth droplette (A. J. Seward, London, England) or by pour
plates in tryptic soy agar (Oxoid) when counts of <10^3
organisms were expected (8). Viable counts are expressed as
geometric means of log$_{10}$ CFU per whole organ ± 1 standard
error of the mean in groups of three to four mice per point.

RESULTS

LD$_{50}$ determinations. Table 1 shows the LD$_{50}$ values of S.
typhimurium M525 (wild type, intermediate virulence strain)
and SL3261 (aroA vaccine strain) in sublethally irradiated
BALB/c mice. Irradiation caused a marked increase in
susceptibility to M525, with a pronounced drop in the LD$_{50}$.
All irradiated mice died in 8 days. In contrast, irradiation had
little if any effect on the virulence of the aroA SL3261
vaccine strain.

Table 1 also shows the LD$_{50}$s of SL3261 and the virulent
C5 strain in xid mice. The immunodefective male (CBA/N ×
BALB/c)F$_1$ mice were, as expected (16, 17), much more
susceptible to the virulent C5 strain than their immunocom-
petent female littermates, although time to death was longer
than with irradiated BALB/c mice (2 to 3 weeks). On the
other hand, there was no difference in the LD$_{50}$ of the aroA
SL3261 strain for these mice.

FIG. 1. Viable bacterial counts in liver and spleen of irradiated (■) and control (□) mice after i.v. inoculation of 10^6 S. typhimurium
SL3261 or 10^3 S. typhimurium M525. Arrow indicates the inoculum dose. SEM, Standard error of the mean.

FIG. 2. Viable bacterial counts in liver and spleen after i.v. administration of 10^6 S. typhimurium SL3261 in male (immunodefective) (□) and female (immunocompetent) (■) (CBA/N × BALB/c)F₁ mice. Arrow indicates the inoculum dose. SEM, Standard error of the mean.

Kinetics of infection. Figure 1 shows the growth of salmonellae in the liver and spleen of irradiated and control mice. The number of viable M525 bacteria recovered from the spleen and liver increased from day 1 to day 5 at approximately the same rate in irradiated and control mice. After day 5, further growth was suppressed (the plateau phase) in control mice, whereas it continued unchecked to lethal levels in irradiated mice. One of the irradiated mice infected with M525 had very high viable counts (~10^9) on day 4, and these results were not plotted; none of these mice survived beyond day 8. Two unirradiated mice infected with M525 died (days 1 and 15). In contrast, the only difference with the aroA SL3261 strain was in the late clearance phase; the Aro strain persisted longer in the reticuloendothelial system of the irradiated mice than in controls. All mice infected with SL3261 remained apparently healthy, as did four uninfected irradiated controls.

Figure 2 shows the growth curves obtained after i.v. infection of (CBA/N × BALB/c)F₁ male and female mice with a sublethal dose of S. typhimurium SL3261. The pattern of growth was similar in both. All mice remained healthy until the end of the experiment.

DISCUSSION

The present results indicate that moderate immunosuppression which is not in itself life threatening but which causes increased susceptibility to wild-type salmonellae does not seriously affect resistance to an aroA salmonella vaccine strain. Mice immunosuppressed by sublethal irradiation or by virtue of the xid-determined B-cell functional defect were more susceptible to wild-type salmonellae but not to the aroA strain. Whereas the wild-type strains were more virulent in immunosuppressed mice, both in terms of the LD₅₀ and, for M525, invasiveness of host tissue, no such increase was seen for the aroA mutant. This is in keeping with the currently accepted view that the main reason for the attenuation of Aro strains may be linked to their requirement for nutrients not available in the host, rather than to an increased susceptibility to a particular host defense mechanism which, if reduced by immunosuppression, might reverse the attenuation of the strain. This could be an important safety factor when considering use of these mutants in the field.

Sublethal irradiation increases susceptibility to salmonellae in mice by ablating the plateau phase which normally occurs at the end of week 1 of a sublethal infection, coinciding with a marked reduction in peripheral blood leukocyte count (3). The precise mechanism responsible for the plateau phase in sublethal salmonella infections in mice is unclear, although it is unlikely to be T cell mediated (14, 15). Ablation of the plateau phase by radiation can be prevented by lead shielding of the hind legs of the mice during irradiation or by adoptive transfer of T-cell-depleted bone marrow, suggesting that the plateau phase requires an influx of bone marrow-derived radiation-sensitive cells (C. E. Hormaeche, P. Mastroeni, A. Arena, J. Uddin, and H. S. Joysey, Immunology, in press). Current data from other models such as Listeria infections (12) suggest that monocytes are probably important, but it is possible that other inflammatory cells (polymorphonuclear leukocytes) play a role in this first phase of resistance (2, 11, 19). One mechanism operating in the establishment of the plateau phase in Listeria infections in scid mice is tumor necrosis factor-mediated gamma interferon release from natural killer cells (1). Whatever the mechanism is in salmonellosis, its temporary suppression by irradiation did not enhance the invasiveness of the aroA strain but only retarded its clearance.

The xid B-cell defect causes low serum immunoglobulin M and immunoglobulin G3 levels, poor or absent responses to certain T-independent and T-dependent antigens, defective splenic proliferative responses to some B-cell mitogens, and increased susceptibility to in vitro tolerance induction (20–22). It also causes increased susceptibility to wild-type salmonellae, but this occurs later in the infection, with a slow progressive increase in bacterial load (17). Salmonella-infected xid mice are reported to die in weeks 2 and 3 (16, 17), which we confirmed. Again, there was no effect of the xid character on the clearance of the aroA mutant, suggesting that late clearance of the mutant is due to cellular rather than humoral mechanisms. The precise stage at which the xid defect operates is unclear and warrants further investigation.

The present results are encouraging when considering the potential use of live attenuated vaccines. Further work is needed to study the effect of immunosuppression induced by

various means on the clearance of these strains. The current results suggest that these strains may not be a major health hazard in immunocompromised populations.

LITERATURE CITED

1. **Bancroft, G. J., K. C. F. Sheehan, R. D. Schreiber, and E. Unanue.** 1989. Tumor necrosis factor is involved in the T cell independent pathway of macrophage activation in *scid* mice. J. Immunol. **143:**127–130.
2. **Campbell, P. A.** 1986. Are inflammatory phagocytes responsible for resistance to facultative intracellular bacteria? Immunol. Today **7:**70–72.
3. **Collins, F. M.** 1979. Mucosal defences against salmonella infection in the mouse. J. Infect. Dis. **139:**503–510.
4. **Dougan, G., C. E. Hormaeche, and D. J. Maskell.** 1987. Live oral salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system. Parasite Immunol. **9:**151–160.
5. **Dougan, G., L. Smith, and F. Heffron.** 1989. Live bacterial vaccines and their application as carriers for foreign antigens. p. 271–299. *In* J. L. Bittle and F. L. Murphy (ed.), Vaccine biotechnology. Academic Press, Inc., Orlando, Fla.
6. **Eisenstein, T. K., and B. M. Sultzer.** 1983. Immunity to salmonella infections. Adv. Exp. Med. Biol. **162:**261–296.
7. **Hoiseth, S. K., and B. A. D. Stocker.** 1981. Aromatic dependent *Salmonella typhimurium* are non-virulent and effective as live vaccines. Nature (London) **291:**238–239.
8. **Hormaeche, C. E.** 1979. Natural resistance to *Salmonella typhimurium* in different inbred mouse strains. Immunology **37:**311–318.
9. **Hormaeche, C. E.** 1979. The natural resistance of radiation chimeras to *S. typhimurium* C5. Immunology **37:**329–332.
10. **Hormaeche, C. E., M. C. Fahrenkrog, R. A. Pettifor, and J. Brock.** 1981. Acquired immunity to *Salmonella typhimurium* and delayed (footpad) hypersensitivity in BALB/c mice. Immunology **43:**547–554.
11. **Hsu, H.** 1989. Pathogenesis and immunity in murine salmonellosis. Microbiol. Rev. **53:**390–409.
12. **Kaufmann, S. H. E.** 1988. Immunity against intracellular bacteria: biological effector function and antigen specificity of T-lymphocytes. Curr. Top. Microbiol. Immunol. **138:**141–176.
13. **Levine, M. M., J. B. Kaper, R. E. Black, and M. L. Clements.** 1983. New knowledge of pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. **47:**510–550.
14. **Maskell, D. J., C. E. Hormaeche, K. A. Harrington, H. S. Joysey, and F. Y. Liew.** 1987. The initial suppression of bacterial growth in a salmonella infection is mediated by a localized rather than a systemic response. Microb. Pathog. **2:**295–305.
15. **O'Brien, A. D., and E. S. Metcalf.** 1982. Control of early *Salmonella typhimurium* growth in innately *Salmonella*-resistant mice does not require functional T cells. J. Immunol. **129:**1349–1351.
16. **O'Brien, A. D., I. Scher, G. H. Campbell, R. P. MacDermott, and S. B. Formal.** 1979. Susceptibility of CBA/N mice to infection with *Salmonella typhimurium*: influence of the X-linked gene controlling B-lymphocyte function. J. Immunol. **123:**720–724.
17. **O'Brien, A. D., I. Scher, and E. S. Metcalf.** 1981. Genetically conferred defect in anti salmonella antibody formation renders CBA/N mice innately susceptible to *Salmonella typhimurium* infection. J. Immunol. **126:**1368–1372.
18. **Reed, L. J., and H. Muench.** 1938. A simple method for estimating fifty per cent endpoints. Am. J. Hyg. **27:**493–496.
19. **Roberts, E. C., J. C. Demartini, and I. M. Orme.** 1987. Passive transfer of acquired resistance to *Listeria monocytogenes* infection is independent of mononuclear cell granuloma formation. Infect. Immun. **55:**3215–3218.
20. **Scher, I.** 1981. B lymphocyte development and heterogeneity: analysis with the immune defective CBA/N mouse strain. p. 163–190. *In* E. Gerschwin and B. Merchant (ed.), Immune defects in laboratory animals. Plenum Publishing Corp., New York.
21. **Scher, I., A. Ahmed, D. M. Strong, A. D. Steinberg, and W. E. Paul.** 1975. X-linked B-lymphocyte immune defect in CBA/HN mice. I. Studies of the function and composition of spleen cells. J. Exp. Med. **141:**788–803.
22. **Scher, I., A. D. Steinberg, and W. E. Paul.** 1975. X-linked B-lymphocyte immune defect in CBA/N mice. II. Studies of the mechanisms underlying the immune defect. J. Exp. Med. **142:**637–650.